What is the most common cause of male urinary incontinence?

Post-prostatectomy incontinence (PPI) is the most common cause overall. Most men experience some degree of leakage in the early weeks and months after radical prostatectomy because the surgery can damage or shorten the external urethral sphincter. Around 80–90% recover acceptable continence within 12 months; persistent moderate-to-severe incontinence at 12 months affects approximately 5–10%. Benign prostatic hyperplasia (BPH) causing chronic urinary retention with overflow dribbling is the second most common pattern, followed by neurogenic bladder from Parkinson's disease, multiple sclerosis, diabetic autonomic neuropathy, or stroke.

What is pelvic floor muscle training and how does it help male incontinence?

Pelvic floor muscle training (PFMT) involves regularly contracting the levator ani and external sphincter muscles that support the urethra and bladder base. Strengthening these muscles reduces leakage with physical activity (stress incontinence) and helps inhibit bladder urgency. For post-prostatectomy incontinence, starting PFMT before surgery and continuing it afterward shortens the duration and severity of post-operative leakage. Supervised training by a continence physiotherapist — using biofeedback or electrical stimulation — is more effective than unsupervised home exercises alone. An 8–12 week supervised course is standard. Find an accredited physiotherapist through the Continence Foundation at continence.org.au.

What medications are used for male urinary incontinence?

The choice depends on the mechanism. For overactive bladder (urge incontinence), mirabegron 50 mg daily (PBS Authority Required) is preferred in older men because it has a lower anticholinergic burden and better cognitive safety profile than traditional agents. Anticholinergics such as solifenacin, oxybutynin, and tolterodine are effective but are listed on the Beers Criteria for older adults given cognitive and falls risks. For overflow from BPH, alpha-blockers (tamsulosin 400 µg) with or without a 5-alpha-reductase inhibitor are first-line. Duloxetine is occasionally used off-label for stress incontinence with informed-consent discussion of risks including nausea and suicidality.

What is the Continence Aids Payment Scheme and who qualifies?

The Continence Aids Payment Scheme (CAPS) is a Commonwealth subsidy administered by Services Australia that provides approximately $650 per year (indexed) towards the cost of continence pads and products for eligible Australians. To qualify, a person must have a permanent and severe incontinence condition, be an Australian resident, and hold a current Medicare card. A GP, nurse, or continence specialist must complete a CAPS assessment form confirming the diagnosis and severity. Patients apply at servicesaustralia.gov.au. The Continence Foundation helpline (1800 33 00 66) assists with the application process and finding local continence services.

When is surgery the right option for male urinary incontinence?

Surgery is considered after at least three to six months of supervised pelvic floor training and appropriate pharmacotherapy have not achieved acceptable continence. For post-prostatectomy stress incontinence, the artificial urinary sphincter (AUS) is the gold-standard procedure for moderate-to-severe leakage — achieving acceptable continence in 80–90% of patients. The male transobturator sling is a less invasive alternative for mild-to-moderate incontinence. Intradetrusor botulinum toxin A is used by urologists for refractory overactive bladder. Sacral neuromodulation is another specialist option. All surgical options require urology referral and urodynamic evaluation.

Male urinary incontinence

Male urinary incontinence: types, treatment, and the AU continence pathway

By Dr HB Lo, FACRRM Reviewed 3 September 2026 10 min read

Male urinary incontinence is involuntary urine loss; the most common cause is post-prostatectomy incontinence, followed by overactive bladder and urinary retention from BPH.

Supervised pelvic floor muscle training (PFMT) with a continence physiotherapist is the cornerstone of treatment; for overactive bladder, mirabegron is preferred over anticholinergics in older men due to lower cognitive risk.

The Continence Foundation helpline (1800 33 00 66) and the Commonwealth Continence Aids Payment Scheme assist with support and equipment costs.

A common problem that is rarely volunteered

Male urinary incontinence — involuntary loss of urine — affects approximately 10–13% of community-dwelling men in Australia. Prevalence rises markedly with age and increases further after prostate surgery, with an estimated four million Australians of all genders experiencing incontinence at any given time (Continence Foundation of Australia). The economic and social cost is estimated at $67 billion annually.

Despite this, incontinence remains severely underreported. Men are particularly unlikely to disclose bladder symptoms voluntarily, citing embarrassment, an assumption that leakage is inevitable with age, and limited awareness that effective treatments exist. GPs who ask directly — as part of a health assessment, chronic disease review, or prostate follow-up — identify cases that would otherwise be managed with pads alone for years.

Seek urgent review if urinary leakage is accompanied by: sudden neurological deterioration; bilateral lower-limb weakness with saddle anaesthesia and bowel dysfunction (cauda equina syndrome — spinal emergency); macroscopic haematuria with clots; or frank urinary retention causing distress.

A. Core clinical — the AU general-practice framework

Classification

eTG (Genitourinary) and USANZ classify male urinary incontinence by mechanism:

Stress urinary incontinence (SUI) — leakage with physical activity (cough, sneeze, lifting, positional change); caused by sphincter incompetence.
Urge urinary incontinence (UUI) — sudden, compelling urge to void followed by involuntary leakage; caused by detrusor overactivity (overactive bladder, OAB).
Mixed urinary incontinence — features of both stress and urge.
Overflow incontinence — continuous or post-void dribbling from incomplete bladder emptying and elevated post-void residual; caused by bladder outlet obstruction (BPH, urethral stricture) or an underactive, neurogenic bladder.
Functional incontinence — physically intact lower urinary tract but physical or cognitive inability to reach the toilet in time.
Post-prostatectomy incontinence (PPI) — stress incontinence arising from sphincter disruption or shortening during radical prostatectomy; the most common cause of male incontinence overall.
Climacturia — leakage at orgasm; a variant of PPI; responds to pelvic floor training.

History

A focused history should cover:

Pattern and timing — leakage with exertion (stress); leakage with urgency (OAB); continuous dribbling (overflow, fistula); leakage at orgasm (PPI variant).
Surgical history — radical prostatectomy, transurethral resection of the prostate (TURP), urethroplasty, pelvic radiotherapy.
Neurological history — Parkinson’s disease, multiple sclerosis, diabetic autonomic neuropathy, stroke, spinal cord injury.
Drug review — anticholinergic agents, opioids, alpha-agonists, diuretics, and alcohol or caffeine all worsen incontinence.
LUTS screen — urinary frequency, nocturia, weak stream, hesitancy, incomplete emptying.
Mental health and quality-of-life impact — incontinence carries a major depression and adjustment-disorder burden; social withdrawal, sexual dysfunction, and relationship strain are common.

A bladder diary completed over three days quantifies the frequency, timing, and volume of leakage and informs the treatment plan.

Examination and investigations

Physical examination:

Abdomen — palpable bladder (suggesting retention).
Digital rectal examination — prostate size, sphincter tone, faecal impaction.
Neurological screen — perineal sensation (S2–S4), bulbocavernosus reflex, lower limb power and reflexes.
Cough stress test with a comfortably full bladder — observe for immediate leakage (stress).
Gait, mobility, and cognitive assessment — functional incontinence contributors.

Investigations per RACGP continence assessment guidance:

Urinalysis and MSU microscopy, culture and sensitivity (MBS item 69300) — exclude urinary tract infection, which acutely worsens urgency.
U&E and creatinine (MBS item 66500) — identify renal impairment from chronic overflow obstruction.
HbA1c or fasting glucose — diabetic autonomic neuropathy is a reversible contributor.
PSA per shared decision in selected patients — especially where prostate cancer or significant BPH is in the differential.
Post-void residual (PVR) by bladder scanner (MBS item 55070 range) — a PVR >100–150 mL is significant; >300 mL warrants urgent urology input.
Pad weight test (24-hour) — quantifies severity: mild <100 g, moderate 100–400 g, severe >400 g per 24 hours.

Specialist investigations (urology): urodynamics to characterise mechanism (detrusor activity, compliance, sphincter function, voiding efficiency); cystoscopy to exclude bladder pathology, fistula, or stricture; MRI for complex anatomy or post-radiation change.

Reversible causes to screen for before escalating

Before initiating pharmacotherapy or specialist referral, always check:

Urinary tract infection — transient urgency and urge incontinence; treat and reassess at four to six weeks.
Faecal impaction — elevates intravesical pressure and worsens both stress and urge incontinence; examine rectally, treat with osmotic laxatives.
Drug-induced — anticholinergic agents (antihistamines, tricyclics, some antipsychotics), opioids, and alpha-agonists all impair detrusor function; diuretics worsen timing. Review and rationalise where safe.
Fluid intake — excess caffeine or total fluid volume; optimise to 1.5–2 L/day distributed across the day; restrict evening intake for nocturia.

B. Conservative management: pelvic floor training and pharmacotherapy

Pelvic floor muscle training — the cornerstone

eTG, USANZ, and multiple Cochrane systematic reviews converge on supervised pelvic floor muscle training (PFMT) as first-line treatment for stress incontinence and post-prostatectomy incontinence.

Refer to a continence physiotherapist — accredited providers are listed at continence.org.au.
Start PFMT before radical prostatectomy — pre-operative training reduces the duration and severity of post-operative incontinence.
A supervised 8–12 week course with biofeedback (real-time display of pelvic floor EMG) or electrical stimulation adjuncts is substantially more effective than unsupervised home exercises alone.
Daily home exercises continue between supervised sessions; adherence is the primary determinant of outcome.

Bladder retraining is first-line for overactive bladder:

Scheduled voiding — initially every two to three hours, extending the interval by 15–30 minutes each week as urgency control improves.
Urge suppression — contract the pelvic floor and use distraction at the point of urgency; never rush to the toilet.
Double voiding for overflow — void, wait 30–60 seconds, then void again.

Lifestyle modifications relevant to all types:

Weight loss in overweight patients — reduces intra-abdominal pressure.
Smoking cessation — reduces chronic cough (worsens stress incontinence) and bladder cancer risk.
Caffeine and alcohol moderation — both worsen detrusor excitability.
Constipation treatment — see our general practice pathway for functional constipation.

Pharmacotherapy

Per AMH and eTG:

Overactive bladder / urge incontinence:

Mirabegron 50 mg daily (beta-3 adrenoceptor agonist, PBS Authority Required) — first-line in older men because of its lower anticholinergic burden, less cognitive impairment, less constipation, and fewer falls compared with anticholinergic agents. Monitor blood pressure; mild hypertension is a class effect.
Anticholinergics (solifenacin 5–10 mg, oxybutynin, tolterodine, darifenacin — all PBS Authority Required for OAB) — effective but listed on the Beers Criteria for older adults given cognitive, falls, constipation, and urinary retention risks. Long-term observational data raise a dementia signal; use sparingly, reassess every 3–6 months, and prefer mirabegron in patients over 65.

Overflow incontinence from BPH:

Alpha-blockers — tamsulosin 400 µg daily reduces bladder neck resistance within days; prazosin, alfuzosin, and silodosin are alternatives. Monitor for postural hypotension.
5-alpha-reductase inhibitors (5ARI) — finasteride 5 mg or dutasteride 0.5 mg (PBS Authority for BPH) reduce prostate volume over 3–6 months and are most effective in glands >30 mL. PSA is halved by 5ARI — adjust the clinical threshold accordingly.

Stress incontinence (selected cases):

Duloxetine 40 mg twice daily — increases urethral sphincter tone via serotonin-noradrenaline reuptake inhibition; off-label in Australia for SUI. Discuss side effects including nausea, dry mouth, and suicidality risk; obtain informed consent; monitor closely in the first four weeks.

Post-prostatectomy incontinence:

PFMT is first-line. Pharmacotherapy has limited specific evidence for PPI. Refer to urology at 6–12 months if PFMT is insufficient.

C. Surgical options and when to refer to urology

Urology referral is appropriate when conservative management — a minimum of three to six months of physiotherapy-supervised PFMT plus appropriate pharmacotherapy — has not achieved acceptable continence. Urodynamic studies characterise the mechanism and guide operative planning.

Artificial urinary sphincter (AUS) — the gold-standard surgical procedure for moderate-to-severe post-prostatectomy stress incontinence, endorsed by both AUA and USANZ. An inflatable cuff surrounds the bulbar urethra and is controlled by a scrotal pump. Achieves acceptable continence in 80–90% of patients; mechanical revision is required in approximately 15–25% at 10 years. Best outcomes in patients with stable, non-radiated tissue.

Male transobturator sling — less invasive option for mild-to-moderate post-prostatectomy incontinence; compresses the posterior urethra. Lower continence rates than AUS for moderate-to-severe incontinence; suitable when the patient wishes to avoid the complexity of AUS or when post-void dribbling predominates.

Urethral bulking agents — injectable periurethral agents (polyacrylamide hydrogel); minimally invasive outpatient procedure; limited durability (12–24 months); selected mild stress incontinence.

Intradetrusor botulinum toxin A — effective for refractory OAB not responding to two pharmacotherapy agents; typically 100 units of onabotulinumtoxinA injected at 20–30 sites under cystoscopy. Significant risk of urinary retention requiring clean intermittent self-catheterisation (CISC) in 5–10%; repeated every 6–12 months as effect wanes.

Sacral neuromodulation (SNM) — an implanted device delivers low-level electrical stimulation to the S3 sacral nerve root. Effective for refractory OAB, non-obstructive urinary retention, and faecal incontinence; specialist procedure; reversible and adjustable.

Indwelling or suprapubic catheter — last resort for refractory severe overflow incontinence or patients unable to perform CISC. Document a thorough discussion of ongoing UTI, encrustation, and quality-of-life implications. Suprapubic catheter is preferred over urethral for long-term use.

D. Australian operations

National support services

Continence Foundation of Australia — national helpline 1800 33 00 66; online continence physiotherapist directory, condition-specific fact sheets, and CAPS application support at continence.org.au.
National Continence Program — Department of Health and Aged Care funded; supports access to community-based continence assessment and management.
Continence Aids Payment Scheme (CAPS) — approximately $650/year Commonwealth subsidy for eligible patients; apply at Services Australia. GP completes a CAPS assessment form documenting diagnosis and severity.
NDIS — patients with disability-related incontinence may access continence assessment, PFMT, and consumables through NDIS where eligible.
DVA — eligible veterans covered through the Repatriation Pharmaceutical Benefits Scheme (RPBS) for medications and the Rehabilitation Appliances Program (RAP) for equipment.
Healthy Male / Andrology Australia — men-specific consumer resources and GP clinical resources at healthymale.org.au.

MBS billing

Standard consultations — MBS 23, 36, 44.
Complex chronic care — MBS 132/133 for comprehensive incontinence review in complex patients.
GP Chronic Condition Management Plan (GPCCMP) — MBS 965/967 (replaced GPMP/TCA from 1 July 2025): appropriate for chronic incontinence with comorbidities; enables allied health referral (continence physiotherapy sessions under the GPCCMP allied health items).
Mental Health Treatment Plan — MBS 2715/2717: significant depression, adjustment disorder, and social isolation are common; offer MHTP and psychology referral routinely.
Multidisciplinary case conferencing — MBS 707: coordinating urology, continence physiotherapy, dietitian, and aged care services.
Pathology — urinalysis MBS 69300, U&E MBS 66500, HbA1c, PSA MBS 66655.
Bladder ultrasound (PVR) — MBS 55070 range.
ATSI Health Assessment — MBS 715: include a continence screen.
Practice nurse — MBS 10997: delegate initial continence history and bladder diary orientation.

E. Special populations

Older adults and frailty. Anticholinergic agents carry significant risk in older or frail patients — cognitive impairment, constipation, urinary retention, falls, and a dementia signal in long-term observational cohorts. Mirabegron 50 mg is the strongly preferred first-line agent. Functional incontinence from mobility impairment or cognitive decline warrants occupational therapy review for toilet access modifications, bed-side commode, and timed voiding programs. Engage aged-care services and the patient’s family or carer in the care plan.

Neurogenic bladder. Parkinson’s disease, multiple sclerosis, diabetic autonomic neuropathy, stroke, and spinal cord injury all cause neurogenic bladder dysfunction — typically a mix of detrusor overactivity and impaired sphincter coordination. Urodynamic characterisation by a urologist is essential before committing to management. Clean intermittent self-catheterisation (CISC) is the standard approach for significant neurogenic retention; where CISC is not feasible or tolerated, a suprapubic catheter is preferred for long-term use.

Post-prostatectomy — peri-operative counselling. Before radical prostatectomy, counsel the patient that temporary incontinence is expected and that PFMT starting pre-operatively shortens recovery time. Provide the Continence Foundation’s pre-surgery fact sheet. Discuss climacturia as a common post-prostatectomy variant that is emotionally significant but usually improves with PFMT. Offer a Mental Health Treatment Plan in the post-operative period — adjustment disorder and depression are common after prostate cancer treatment.

Mental health. Incontinence carries a major quality-of-life burden. Social withdrawal, sexual dysfunction, occupational impairment, and relationship strain lead to clinically significant depression and adjustment disorder in a substantial proportion of affected men. Routine screening with PHQ-9 or K10 at every review; offer MHTP and psychology referral when indicated; document the offer.

When to escalate

Refer to urology when:

Post-prostatectomy incontinence persists beyond 6–12 months despite supervised PFMT.
Overflow incontinence with post-void residual >300 mL, or a rising creatinine — risk of obstructive nephropathy.
Macroscopic haematuria with or without incontinence — bladder cancer and urolithiasis must be excluded.
Suspected urethral stricture (poor and intermittent stream, post-instrumentation history).
OAB refractory to two pharmacotherapy agents.
Suspected or confirmed neurogenic bladder — for urodynamic characterisation and specialist co-management.
Continuous leakage suggesting a urinary fistula (post-radiation, post-pelvic surgery, malignancy).
Patient preference for surgical management after informed discussion of conservative options.

What this article is and is not

This is general health information drawn from eTG, AMH, USANZ, and RACGP continence guidelines. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about specific investigations, pharmacotherapy, and referral are made with your own GP.

For Australian consumer-friendly information and support: Continence Foundation Australia 1800 33 00 66, HealthDirect — Urinary incontinence in men, Healthy Male / Andrology Australia, and Better Health Channel.

Sources cited

Frequently asked questions

What is the most common cause of male urinary incontinence?

Post-prostatectomy incontinence (PPI) is the most common cause overall. Most men experience some degree of leakage in the early weeks and months after radical prostatectomy because the surgery can damage or shorten the external urethral sphincter. Around 80–90% recover acceptable continence within 12 months; persistent moderate-to-severe incontinence at 12 months affects approximately 5–10%. Benign prostatic hyperplasia (BPH) causing chronic urinary retention with overflow dribbling is the second most common pattern, followed by neurogenic bladder from Parkinson's disease, multiple sclerosis, diabetic autonomic neuropathy, or stroke.
What is pelvic floor muscle training and how does it help male incontinence?

Pelvic floor muscle training (PFMT) involves regularly contracting the levator ani and external sphincter muscles that support the urethra and bladder base. Strengthening these muscles reduces leakage with physical activity (stress incontinence) and helps inhibit bladder urgency. For post-prostatectomy incontinence, starting PFMT before surgery and continuing it afterward shortens the duration and severity of post-operative leakage. Supervised training by a continence physiotherapist — using biofeedback or electrical stimulation — is more effective than unsupervised home exercises alone. An 8–12 week supervised course is standard. Find an accredited physiotherapist through the Continence Foundation at continence.org.au.
What medications are used for male urinary incontinence?

The choice depends on the mechanism. For overactive bladder (urge incontinence), mirabegron 50 mg daily (PBS Authority Required) is preferred in older men because it has a lower anticholinergic burden and better cognitive safety profile than traditional agents. Anticholinergics such as solifenacin, oxybutynin, and tolterodine are effective but are listed on the Beers Criteria for older adults given cognitive and falls risks. For overflow from BPH, alpha-blockers (tamsulosin 400 µg) with or without a 5-alpha-reductase inhibitor are first-line. Duloxetine is occasionally used off-label for stress incontinence with informed-consent discussion of risks including nausea and suicidality.
What is the Continence Aids Payment Scheme and who qualifies?

The Continence Aids Payment Scheme (CAPS) is a Commonwealth subsidy administered by Services Australia that provides approximately $650 per year (indexed) towards the cost of continence pads and products for eligible Australians. To qualify, a person must have a permanent and severe incontinence condition, be an Australian resident, and hold a current Medicare card. A GP, nurse, or continence specialist must complete a CAPS assessment form confirming the diagnosis and severity. Patients apply at servicesaustralia.gov.au. The Continence Foundation helpline (1800 33 00 66) assists with the application process and finding local continence services.
When is surgery the right option for male urinary incontinence?

Surgery is considered after at least three to six months of supervised pelvic floor training and appropriate pharmacotherapy have not achieved acceptable continence. For post-prostatectomy stress incontinence, the artificial urinary sphincter (AUS) is the gold-standard procedure for moderate-to-severe leakage — achieving acceptable continence in 80–90% of patients. The male transobturator sling is a less invasive alternative for mild-to-moderate incontinence. Intradetrusor botulinum toxin A is used by urologists for refractory overactive bladder. Sacral neuromodulation is another specialist option. All surgical options require urology referral and urodynamic evaluation.

Source quality

Sources grouped by evidence tier. AU primary tier first; international where AU is silent or lagging; named-author reconstruction where guidelines have not yet caught up. How tiers work.